Detalhe da pesquisa
1.
1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.
Bioorg Med Chem Lett
; 28(11): 2103-2108, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29709252
2.
Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats.
Mol Pain
; 122016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27899696
3.
Development of novel azabenzofuran TRPA1 antagonists as in vivo tools.
Bioorg Med Chem Lett
; 24(15): 3464-8, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24953819
4.
Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones.
J Org Chem
; 77(8): 3887-906, 2012 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22458369
5.
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
Bioorg Med Chem Lett
; 19(2): 424-7, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19062275
6.
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
J Med Chem
; 50(4): 611-26, 2007 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17253678
7.
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.
J Med Chem
; 50(4): 627-40, 2007 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17253679
8.
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
J Med Chem
; 49(19): 5671-86, 2006 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-16970394
9.
Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.
J Med Chem
; 59(6): 2794-809, 2016 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26942860
10.
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.
J Med Chem
; 58(13): 5189-207, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25970324
11.
Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Exp Hematol
; 41(5): 491-500, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23340136
12.
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
J Med Chem
; 54(24): 8440-50, 2011 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22087750
13.
Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index.
J Med Chem
; 53(11): 4502-10, 2010 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20459125
14.
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
J Med Chem
; 53(17): 6368-77, 2010 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-20684549
15.
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Cancer Res
; 70(23): 9846-54, 2010 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20935223
16.
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.
Bioorg Med Chem Lett
; 17(10): 2886-9, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17350837